Clopidogrel Bisulfate
Product Images NDC 70400-101

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 70400-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sterisyn Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Clopidogrel Tablets 30 Final)

Clopidogrel bisulfate tablets, USP 75 mg by Sterisyn Scientific. The label shows product NDC 70400-101-30 and indicates 30 tablets per bottle. It includes storage instructions, dosage information, and a barcode. Manufactured by SciGen Pharmaceuticals, Inc., and marketed by Sterisyn Inc.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A horizontal bar chart depicting the effect of different proton pump inhibitors (PPIs) on exposure to clopidogrel active metabolite following multiple doses of clopidogrel 75 mg alone or with PPIs. The chart shows mean and 90% confidence intervals of active metabolite AUC change relative to clopidogrel administered alone for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line chart comparing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up for patients treated with placebo plus aspirin and clopidogrel plus aspirin. The chart shows a lower event rate for the clopidogrel group compared to the placebo group, with a statistical significance value (P=0.00009).*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A forest plot chart depicting hazard ratios with 95% confidence intervals for Clopidogrel bisulfate versus placebo across various patient subgroups including age, gender, race, comorbid conditions, and concurrent medications. The chart displays numerical values and percentage outcomes for Clopidogrel and placebo groups, illustrating the comparative effectiveness and favorability of Clopidogrel in each subgroup.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A cumulative event rate curve for death in the COMMIT Study comparing placebo and Clopidogrel groups. The y-axis shows percent dead before first discharge, and the x-axis shows days since randomization (up to 28 days). The placebo group had 1845 deaths (8.1%), while the Clopidogrel group had 1726 deaths (7.5%), with a 7% proportional risk reduction (p=0.03). All treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A Kaplan-Meier curve displaying the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The chart compares two groups: placebo with 10.1% events (2310 patients) and clopidogrel with 9.2% events (2121 patients), showing a 9% proportional risk reduction (p=0.002).*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot figure showing effects of adding Clopidogrel to Aspirin on the combined primary endpoint across baseline and concomitant medication subgroups in the COMMIT study. It presents odds ratios with 99% confidence intervals for subgroups based on gender, age, time since onset, systolic blood pressure, heart rate, and use of fibrinolytic agents.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up comparing Aspirin and Clopidogrel. The graph plots event rates on the y-axis against months on the x-axis, with Clopidogrel showing a slightly lower event rate than Aspirin throughout the period. A p-value of 0.045 is indicated on the graph.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study,' displaying hazard ratios for stroke, MI, PAD, and overall conditions comparing Clopidogrel and Aspirin. Percentages and event counts are shown for each group, with a horizontal axis representing hazard ratio values from 0.6 to 1.3.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate, showing the molecular arrangement including a thiophene ring, a chlorophenyl group, and a methyl ester functional group, along with the presence of sulfuric acid (H2SO4) as part of the bisulfate salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.